Parkwood LLC Bei Gene, Ltd. Transaction History
Parkwood LLC
- $804 Million
- Q2 2024
A detailed history of Parkwood LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Parkwood LLC holds 9,055 shares of BGNE stock, worth $2.09 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
9,055
Previous 11,330
20.08%
Holding current value
$2.09 Million
Previous $1.77 Million
27.09%
% of portfolio
0.16%
Previous 0.16%
Shares
15 transactions
Others Institutions Holding BGNE
# of Institutions
212Shares Held
45.1MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.44 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.62 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.2 Billion19.1% of portfolio
-
Primecap Management CO Pasadena, CA4.99MShares$1.15 Billion0.52% of portfolio
-
Baillie Gifford & CO3.68MShares$852 Million0.42% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $24B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...